Targets › VKORC1
7 programs from 7 companies in 7 trials: 5 Phase 4, 2 Phase 3; Cardiovascular, Other, Genitourinary; next expected readout Dec 2026.
Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. (UniProt, Q9BQB6)
Open in Phaseline: the race on VKORC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hospital Sirio-Libanes | Warfarin Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | VKORC1 | Phase 4 | Atrium; Fibrillation | Dec 2026 |
| Nicholas Carlson | Warfarin Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | VKORC1 | Phase 4 | Atrial Fibrillation and Flutter | Jan 2027 |
| Columbia University | Warfarin Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | VKORC1 | Phase 4 | Bleeding | Apr 2027 |
| University of Michigan | Vitamin K Vitamin K cofactor for gamma-carboxylation of clotting factors | VKORC1 | Phase 4 | Anticoagulant Therapy | – |
| China National Center for Cardiovascular Diseases | Warfarin Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | VKORC1 | Phase 4 | Anticoagulation | – |
| Population Health Research Institute | Warfarin Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | VKORC1 | Phase 3 | Bleeding Post-mechanical Valve Replacement | Dec 2028 |
| University of Sydney | Vitamin K1 (Phytonadione) Vitamin K-dependent carboxylation factor | VKORC1 | Phase 3 | Calciphylaxis | Dec 2029 |
Bleeding Post-mechanical Valve Replacement (1) Bleeding (1) Atrium; Fibrillation (1) Calciphylaxis (1) Atrial Fibrillation and Flutter (1) Anticoagulant Therapy (1) Anticoagulation (1)
small molecule (7)
Population Health Research Institute (1) Columbia University (1) Hospital Sirio-Libanes (1) University of Sydney (1) Nicholas Carlson (1) University of Michigan (1) China National Center for Cardiovascular Diseases (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.